Phoenix Molecular Imaging
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Phoenix Molecular Imaging sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Phoenix Molecular Imaging: 2 sponsored US clinical trials, none currently recruiting.
Phoenix Molecular Imaging sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Adenocarcinoma, with 1 trials.
Mid-pack sponsor footprint
Phoenix Molecular Imaging is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
How the Phoenix Molecular Imaging early-phase archive is shaped
2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Prostate Adenocarcinoma (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Phoenix Molecular Imaging: archived-pipeline peers nationwide
Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Phoenix Molecular Imaging sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 archived trials
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Phoenix Molecular Imaging page
2 registered trials is a research-attention snapshot, not an endorsement of Phoenix Molecular Imaging or any single study.
- None of Phoenix Molecular Imaging's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Prostate Adenocarcinoma is the condition Phoenix Molecular Imaging studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Adenocarcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Phoenix Molecular Imaging pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.